Clinical and biological database for people with advanced ovarian, peritoneal, or fallopian tube cancer
Study of Prognostic Factors Associated With Overall Survival in Patients Initially Treated for Advanced Ovarian and/or Peritoneum and/or Fallopian Tubes Carcinoma: Analysis Using a Prospective Clinico-Biological Database
NA · Centre Oscar Lambret · NCT06969833
This project will collect clinical information, blood and tumor samples, and regular quality-of-life questionnaires from people newly diagnosed with advanced ovarian, peritoneal, or fallopian tube cancer to see if combining patient and tumor features can predict overall survival.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 371 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Oscar Lambret (other) |
| Locations | 1 site (Lille) |
| Trial ID | NCT06969833 on ClinicalTrials.gov |
What this trial studies
This is a prospective, observational database run at the Centre Oscar Lambret that will enroll patients at the time of initial care and confirm inclusion when FIGO stage IIB–IV is established. Participants give consent for an extra blood draw, leftover routine tumor and fluid samples, and repeated quality-of-life and anxiety questionnaires over a two-year active participation period. Clinical, biological, and patient-reported data are entered into a trial-specific database with the goal of building prognostic models of overall survival. The project plans to recruit 371 patients over five years and will continue to collect standard-care and survival data beyond the active participation window.
Who should consider this trial
Good fit: Adults treated at the Centre Oscar Lambret with a confirmed diagnosis of advanced invasive ovarian, primary peritoneal, or fallopian tube carcinoma (FIGO IIB–IV) who can give informed consent are ideal candidates.
Not a fit: People with early-stage disease (FIGO IA–IIA), those whose diagnosis is not confirmed as advanced invasive ovarian/peritoneal/fallopian tube cancer, or those unable or unwilling to consent are not expected to benefit from inclusion.
Why it matters
Potential benefit: If successful, the work could help clinicians predict prognosis more accurately and tailor treatment and follow-up for people with advanced ovarian, peritoneal, or fallopian tube cancer.
How similar studies have performed: Prospective biobanks and prognostic modeling efforts in ovarian cancer have produced promising associations between clinical/molecular features and outcomes, but prospective validation of integrated models remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility criteria for pre-registration: * Patient aged 18 or over * Informed consent warranted * Patient affiliated to a social security regimen * Suspected diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer (IIB to IV FIGO stages) * Pre-registration during standard care at the Oscar Lambret Centre, from diagnosis and before confirmation of definitive FIGO stage Non eligibility criteria for pre-registration: * Patient deprived of liberty or under curatorship or guardianship * Refusal to participate Inclusion criteria: • Confirmed diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer (IIB to IV FIGO stages) Exclusion criteria: • Dismissed diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer , or other type of cancer
Where this trial is running
Lille
- Centre Oscar Lambret — Lille, France (RECRUITING)
Study contacts
- Study coordinator: Alicia Probst, PhD
- Email: promotion@o-lambret.fr
- Phone: 33320295918
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer of the Ovary, Cancer of the Fallopian Tube, Peritoneal Cancer